521 related articles for article (PubMed ID: 31335355)
1. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
[TBL] [Abstract][Full Text] [Related]
2. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
3. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
[TBL] [Abstract][Full Text] [Related]
4. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.
Parra-Herran C; Lerner-Ellis J; Xu B; Khalouei S; Bassiouny D; Cesari M; Ismiil N; Nofech-Mozes S
Mod Pathol; 2017 Dec; 30(12):1748-1759. PubMed ID: 28776572
[TBL] [Abstract][Full Text] [Related]
5. Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Ovary: Incidence and Morphologic Associations in 109 Cases.
Bennett JA; Morales-Oyarvide V; Campbell S; Longacre TA; Oliva E
Am J Surg Pathol; 2016 May; 40(5):656-63. PubMed ID: 26813747
[TBL] [Abstract][Full Text] [Related]
6. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
[TBL] [Abstract][Full Text] [Related]
7. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
[TBL] [Abstract][Full Text] [Related]
8. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
10. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J
Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142
[TBL] [Abstract][Full Text] [Related]
11. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
Proctor L; Pradhan M; Leung S; Cheng A; Lee CH; Soslow RA; Gilks CB; Talhouk A; McAlpine JM; Danielsen HE; Hoang LN
Gynecol Oncol; 2017 Sep; 146(3):596-602. PubMed ID: 28647100
[TBL] [Abstract][Full Text] [Related]
12. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
[TBL] [Abstract][Full Text] [Related]
13. Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.
Hoang LN; Kinloch MA; Leo JM; Grondin K; Lee CH; Ewanowich C; Köbel M; Cheng A; Talhouk A; McConechy M; Huntsman DG; McAlpine JN; Soslow RA; Gilks CB
Am J Surg Pathol; 2017 Feb; 41(2):245-252. PubMed ID: 28079598
[TBL] [Abstract][Full Text] [Related]
14. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH
Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557
[TBL] [Abstract][Full Text] [Related]
15. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
[TBL] [Abstract][Full Text] [Related]
16. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women.
He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T
Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic analysis with immunohistochemistry for DNA mismatch repair protein expression in synchronous primary endometrial and ovarian cancers.
Kobayashi Y; Nakamura K; Nomura H; Banno K; Irie H; Adachi M; Iida M; Umene K; Nogami Y; Masuda K; Kisu I; Ueki A; Yamagami W; Kataoka F; Hirasawa A; Tominaga E; Susumu N; Aoki D
Int J Gynecol Cancer; 2015 Mar; 25(3):440-6. PubMed ID: 25695547
[TBL] [Abstract][Full Text] [Related]
18. Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are Uncommon.
Baniak N; Fadare O; Köbel M; DeCoteau J; Parkash V; Hecht JL; Hanley KZ; Gwin K; Zheng W; Quick CM; Jarboe EA; Liang SX; Kinloch M
Am J Surg Pathol; 2019 Apr; 43(4):531-537. PubMed ID: 30585826
[TBL] [Abstract][Full Text] [Related]
19. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.
Rambau PF; Duggan MA; Ghatage P; Warfa K; Steed H; Perrier R; Kelemen LE; Köbel M
Histopathology; 2016 Aug; 69(2):288-97. PubMed ID: 26799366
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Mismatch Repair Protein Deficiency and Associated Clinicopathologic Features in a Cohort of 104 Ovarian Endometrioid Carcinomas.
Bennett JA; Pesci A; Morales-Oyarvide V; Da Silva A; Nardi V; Oliva E
Am J Surg Pathol; 2019 Feb; 43(2):235-243. PubMed ID: 30256257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
